|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Here we demonstrate that the development of angiogenesis inhibitor-induced hypertension and albuminuria is solely dependent on the ETA receptor and that an upregulation in PGI2 plays a previously unidentified role in the deleterious effects of angiogenesis inhibitors.
|
31593221 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
These findings highlight the role of endothelin-1 in driving biventricular remodeling secondary to RV hypertension and suggest that early therapy with an endothelin-1 receptor blocker may be beneficial in attenuating biventricular remodeling but that late therapy is also effective.
|
29446710 |
2018 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
G<sub>s</sub>-coupled GPCR signalling is regulated by G protein-coupled receptor kinases (GRK) and arrestin proteins, and dysregulation of Gs/GPCR signalling is thought play a role in the development of hypertension, which may be a consequence of enhanced GRK2 and/or arrestin expression.
|
30075183 |
2018 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
The present study show that hypertension yet prevail after gastric bypass surgery and the ET(A) receptor antagonist BQ123 may be a useful tool in reducing blood pressure in obese hypertensive patients.
|
29947537 |
2018 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
G-protein coupled receptor (GPCR) mediated activation of the MAPK signalling cascade is a key pathway in the induction of hypertrophic remodelling of the heart - a response to pathological cues including hypertension and myocardial infarction.
|
28412414 |
2017 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, the DDAH1 and COL18A1 genes were associated with systolic BP change (P < 1.00 × 10(-6) and P = 4.00 × 10(-6), respectively), while EDNRA was associated with hypertension incidence (P = 2.39 × 10(-4)).
|
25424718 |
2015 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
These include the contribution of variants of the regulator of G protein signaling (RGS) protein to hypertension; the role variants of the activator of G protein signaling (AGS) proteins to phenotypes (such as the type III AGS8 variant to hypoxia); the contribution of G protein-coupled receptor kinase (GRK) proteins, such as GRK4, in disorders such as hypertension.
|
25150869 |
2014 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
In contrast, females are relatively protected from high blood pressure and kidney damage via increased ET(B) versus ET(A) receptor function.
|
22372527 |
2013 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
RGD |
Increased ET-1 and reduced ET(B) receptor expression in uremic hypertensive rats.
|
20144075 |
2010 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Exposure of COX-2 null mice to hypoxia resulted in severe pulmonary hypertension characterized by enhanced pulmonary vascular remodeling and significant up-regulation of the endothelin-1 receptor ET(A)R in the lung after hypoxia.
|
19577709 |
2009 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Systemic hypertension is associated with increased ET-1 and ET(A) receptor mRNA expression, whereas insulin-dependent diabetes down-regulates ET(A) receptor mRNA expression in the internal mammary artery in patients with coronary artery disease undergoing bypass grafting.
|
19653178 |
2009 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In the case of the G protein-coupled receptor kinases (GRKs), identified originally in the retinal tissues that converge on rhodopsin, proteins such as GRK4 have been identified that have been subsequently associated with hypertension.
|
18370232 |
2008 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the rs5335 (C+70G) polymorphism of the EDNRA gene has small effects on the risk of hypertension.
|
18172451 |
2008 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
In addition, an 'uncoupling' of the G-protein-coupled receptor/G-protein complex is the principal mechanism underlying impaired G-protein-coupled-receptor-mediated vasodilatation in hypertension.
|
16481879 |
2006 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In Japanese patients with newly diagnosed, untreated hypertension (n = 184), we studied polymorphisms in 10 genes, including G protein-coupled receptor kinase type 4 (GRK4), some variations of which are associated with hypertension and impair D1 receptor (D1R)-inhibited renal sodium transport.
|
16439609 |
2006 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Further studies are indicated, especially in view of the reported efficacy of endothelin-1 receptor blockers in treating hypoxia-associated pulmonary hypertension.
|
16769575 |
2006 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
RGD |
They also demonstrate that selective blockade of ETA receptors is superior to nonselective ETA/ETB in attenuating hypertension, hypertensive organ damage, and survival rate.
|
16157796 |
2005 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
G-protein-coupled receptor kinases (GRKs) are implicated in the pathophysiology of human diseases such as arterial hypertension, heart failure and rheumatoid arthritis.
|
15225142 |
2004 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
LHGDN |
STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
|
15838366 |
2004 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension.
|
12600921 |
2003 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Chronic ET(A) receptor blockade normalizes blood pressure, prevents upregulation of vascular ET-1, and improves endothelial dysfunction in 11beta-HSD inhibitor-induced hypertension and may emerge as a novel therapeutic approach in cardiovascular disease associated with reduced 11beta-HSD activity.
|
11425780 |
2001 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
These findings demonstrate that endogenous overexpression of preproET-1, accompanied by an elevation of plasma ET-1 concentrations to the levels seen in pathophysiological states, can cause systemic hypertension through the activation of the ETA receptor.
|
8941655 |
1996 |